Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF.

June-Young KohDoo Ri KimSohee SonHwanhee ParkKyung-Ran KimSunwoo MinHa Seok LeeByung Woo JhunEun-Suk KangInkyung JungJi-Man KangYae-Jean KimEui-Cheol Shin

Published in: Journal of clinical immunology (2024)

In a patient with STAT1 GOF, ruxolitinib treatment improved autoimmune features and downregulated aberrantly overexpressed ISGs, but did not correct epigenetic abnormality of ISGs.

Keyphrases

dna methylation
case report
gene expression
cell proliferation
multiple sclerosis
combination therapy
drug induced